FORMULATION ARTICLES
-
Beyond Better Models: Why The Future Of AI-Designed mRNA Depends On More Relevant Biological Data
AI can optimize mRNA only if it's trained on biologically relevant data. Better therapeutic datasets — not just better algorithms — will drive the next generation of RNA medicines.
-
The Delivery Challenge For In Vivo Cell Engineering
As RNA therapies expand beyond the liver, delivery—not payload design—has become the defining challenge for precise, scalable in vivo cell engineering.
-
Building An ASO For TUBB4A-Related Leukodystrophy (Pt. 1)
SynaptixBio CEO Dan Williams explains how the company selected an ASO for TUBB4A leukodystrophy by balancing potency, safety, and translational rigor to advance a rare disease therapy.
-
Location Matters: How The Nuclear Geography Of circRNAs Could Shape The Future Of RNA Therapeutics
CircRNA location may be as important as its sequence. Discover how nuclear organization could influence the next generation of RNA therapeutics.
-
Building The RNA Knowledge Graph: How Better Annotation Is Accelerating Therapeutic Discovery
As RNA therapeutics grow more complex, better biological annotation is becoming the foundation for AI-driven discovery, target selection, and smarter drug development.
-
Building A Self-Driving Lab For LNP Development
With commercially available components, MIT researchers built a platform that accelerates LNP process development, optimization, and autonomous manufacturing research.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Industry experts discuss current and future trends, formulating successful lipid compositions and navigating the constantly evolving genomic medicine landscape.
-
Understand how turbulent-jet mixing ensures predictable and reproducible nanoparticle size and uniformity across all scales, accelerating development and regulatory readiness.
-
Technical summaries and detailed protocols for purity testing, sizing, sequencing and expression analysis of oligonucleotide-based active agents as well as protein and lipid-based delivery systems.
-
Learn about the drug development hurdles that must be overcome to deliver on the promise of mRNA.
-
Examine how a 21‑mer oligo was synthesized and purified through systematic resin screening, method optimization, and successful scale‑up to build reliable, high‑purity chromatography workflows.
-
Understand the advantages and challenges of lipid-based delivery systems for successful translation of RNA into clinical development.
-
Review the regulatory classification of LNPs, liposomes, and novel excipients as well as specific requirements outlined in regulatory guidance documents and strategies to navigate emerging challenges.